$33.57
0.03% day before yesterday
Nasdaq, Oct 31, 09:01 pm CET

Omnicell, Inc. Stock price

$33.57
+3.12 10.25% 1M
+2.31 7.39% 6M
-10.95 24.60% YTD
-15.07 30.98% 1Y
-43.75 56.58% 3Y
-54.05 61.69% 5Y
+5.35 18.96% 10Y
+22.97 216.70% 20Y
Nasdaq, Closing price Fri, Oct 31 2025
-0.01 0.03%

Key metrics

Basic
Market capitalization
$1.5b
Enterprise Value
$1.5b
Net debt
positive
Cash
$425.0m
Shares outstanding
46.4m
Valuation (TTM | estimate)
P/E
68.5 | 21.2
P/S
1.3 | 1.3
EV/Sales
1.3 | 1.2
EV/FCF
16.4
P/B
1.2
Financial Health
Equity Ratio
58.6%
Return on Equity
1.0%
ROCE
1.0%
ROIC
0.7%
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$1.1b | $1.2b
EBITDA
$91.3m | $136.6m
EBIT
$15.5m | $78.8m
Net Income
$23.1m | $73.5m
Free Cash Flow
$89.2m
Growth (TTM | estimate)
Revenue
6.4% | 5.5%
EBITDA
43.6% | 55.8%
EBIT
160.3% | 1,334.5%
Net Income
211.4% | 486.2%
Free Cash Flow
-41.2%
Margin (TTM | estimate)
Gross
43.9%
EBITDA
7.9% | 11.7%
EBIT
1.3%
Net
2.0% | 6.3%
Free Cash Flow
7.8%
More
EPS
$0.5
FCF per Share
$1.9
Short interest
6.1%
Employees
4k
Rev per Employee
$300.0k
Show more

Is Omnicell, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.

Omnicell, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Omnicell, Inc. forecast:

10x Buy
71%
4x Hold
29%

Analyst Opinions

14 Analysts have issued a Omnicell, Inc. forecast:

Buy
71%
Hold
29%

Financial data from Omnicell, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1,150 1,150
6% 6%
100%
- Direct Costs 645 645
2% 2%
56%
504 504
12% 12%
44%
- Selling and Administrative Expenses 398 398
3% 3%
35%
- Research and Development Expense 89 89
1% 1%
8%
91 91
44% 44%
8%
- Depreciation and Amortization 76 76
15% 15%
7%
EBIT (Operating Income) EBIT 15 15
160% 160%
1%
Net Profit 23 23
211% 211%
2%

In millions USD.

Don't miss a Thing! We will send you all news about Omnicell, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Omnicell, Inc. Stock News

Positive
The Motley Fool
3 days ago
It scored not one, but two beats on analyst estimates for its third-quarter performance. This, despite a slight year-over-year decline in adjusted profitability.
Neutral
Seeking Alpha
3 days ago
Omnicell, Inc. ( OMCL ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Kathleen Nemeth - Senior Vice President of Investor Relations Randall Lipps - Founder, Executive Chairman, President & CEO H. Radford - Executive VP & CFO Conference Call Participants Jessica Tassan - Piper Sandler & Co., Research Division Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Div...
Neutral
Business Wire
3 days ago
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces Third Quarter 2025 Financial Results.
More Omnicell, Inc. News

Company Profile

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence; platform and interoperability; central pharmacy dispensing; medication adherence; population health; and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Mountain View, CA.

Head office United States
CEO Randall Lipps
Employees 3,670
Founded 1992
Website www.omnicell.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today